Company: SNSE
Filing Date: 2025-04-01
Form Type: PRE 14A
Source: 0000950170-25-048533
Chunk: 57

Company: Sensei Biotherapeutics, Inc.
Filing Date: 2025-04-01
Form: PRE 14A
Chunk 57
---
 our equity compensation plans in effect as of December 31, 2024.

| Plan Category                                              |     | Number of securities to 
 be issued upon exercise 
 of outstanding options, 
 warrants and rights     
 (a)                     |           |     |    | Weighted-average     
 exercise price of    
 outstanding options, 
 warrants and rights  
 (b)                  |      |     |    | Number of securities    
 remaining available for 
 future issuance under   
 equity compensation     
 plans (excluding        
 securities reflected in 
 column (a))             
 (c)                     |           |     |    |
|:-----------------------------------------------------------|:----|:------------------------|----------:|:----|---:|:---------------------|-----:|:----|---:|:------------------------|----------:|:----|---:|
| Equity compensation plans approved by security holders     |     |                         | 5,379,253 |     | -1 | $                    | 4.80 |     | -2 |                         | 2,154,375 |     | -3 |
| Equity compensation plans not approved by security holders |     |                         |   416,872 |     |    | $                    | 9.82 |     |    |                         |         — |     |    |
| Total                                                      |     |                         | 5,796,125 |     |    |                      |      |     |    |                         | 2,154,375 |     |    |

Includes shares issuable upon exercise of outstanding options under our 2018 Plan and 2021 Plan.

The weighted average exercise price is calculated based solely on outstanding stock options. It does not take into account the shares of common stock underlying RSUs, which have no exercise price. There are no warrants outstanding under our equity compensation plans.

Consists of shares available under the 2021 Plan and our 2021 Employee Stock Purchase Plan (the “ESPP”) as of December 31, 2024. On January 1 of each year, the number of shares reserved under the 2021 Plan and the ESPP is automatically increased by 4.0% and 1.0%, respectively, of the total number of shares of common stock that are outstanding at that time, or a lesser number of shares as may be determined by our board of directors. As a result, an additional 1,007,223 shares and 251,805 shares were added to the number of available shares under the 2021 Plan